Studio finanziato dalla Brain Research Foundation Verona.
Articolo pubblicato online il 15 ottobre 2020: https://www.frontiersin.org/articles/10.3389/fimmu.2020.576745/full
© 2020 The Author(s). Published by Frontiers in Immunology.
Autori
Alberto Beretta, Martin Cranage, Donato Zipeto.
Abstract
The serological responses to both SARS-CoV-1 and SARS-CoV-2 virus have some unique characteristics that suggest cross-reactive priming by other human coronaviruses (hCoVs). The early kinetics and magnitude of these responses are, in some cases, associated with worse clinical outcomes in SARS and COVID-19. Cross-reactive hCoV antibody responses have been detected in both SARS and COVID-19 patients. There is also evidence that pre-existing T cell immunity to common cold coronaviruses can prime the response to SARS-CoV-2. Studies in non-human primates show that SARS-CoV-1 S-protein vaccine-induced antibodies are associated with acute lung injury in macaques challenged with SARS-CoV-1. Here we discuss the potential of cross-reactive immunity to drive the immunopathogenesis of COVID-19 and its implications for current efforts to develop immune-based therapies and vaccines.
Responsabile: Alberto Beretta – Solongevity Research, Milano – alberto.beretta@solongevity.com
Articolo open access con licenza CC BY Creative Commons.
